Eli Lilly delivered a landmark quarter for obesity medicine in Q2 2026, posting results that sent its stock soaring and reinforced the company's dominant position in the GLP-1 and incretin therapy space. The earnings report beat Wall Street estimates across the board, driven almost entirely by surging demand for its weight-loss and diabetes drug portfolio. For patients and clinicians following the retatrutide pipeline, the financial picture tells a meaningful story about where the obesity drug landscape is heading — and how quickly.
The numbers were striking by any measure. Mounjaro revenue jumped 91% year-over-year to $9.9 billion in Q2 2026, while Zepbound, Lilly's tirzepatide formulation approved specifically for obesity, brought in $4.9 billion in the same period. Together, these two drugs — both built on the dual GIP/GLP-1 agonist tirzepatide — generated roughly $14.8 billion in a single quarter, underscoring just how profoundly the incretin drug class has reshaped the treatment landscape for obesity and type 2 diabetes.
The strong earnings sent Eli Lilly's stock soaring, reflecting investor confidence that demand for effective weight-loss therapies remains robust and that the company's pipeline — including retatrutide — represents the next chapter in that story. Eli Lilly also raised its full-year 2026 sales forecast following the results, a signal of sustained commercial confidence rather than a one-quarter anomaly.
To appreciate the scale of these figures, it helps to place them in clinical context. Tirzepatide's commercial success is grounded in genuine efficacy data. In the SURMOUNT-1 trial, tirzepatide at 15mg produced a mean weight loss of 20.9% over 72 weeks — a result that set a new benchmark for pharmacologic obesity treatment at the time of its publication. That kind of clinical performance drives real-world patient demand, and the Q2 2026 revenue figures reflect exactly that.
But the revenue story is only partly about what tirzepatide has already achieved. It is equally a story about what comes next. Retatrutide — commonly referred to as reta in patient communities — is Lilly's next-generation compound, and the financial momentum behind Mounjaro and Zepbound is directly funding the infrastructure, manufacturing scale, and regulatory machinery that will eventually bring reta to market.
Retatrutide is a triple agonist, acting simultaneously on GLP-1, GIP, and glucagon receptors. This triple-receptor mechanism — sometimes called "triple G" in patient community discussions — represents a meaningful pharmacological step beyond dual agonism. The glucagon receptor component, in particular, is hypothesized to drive additional energy expenditure and metabolic benefit beyond what GLP-1 or GIP activation alone can achieve. Patients who have followed reta closely often describe hoping it will address not just appetite but also the persistent "food noise" — the intrusive, constant preoccupation with food that makes weight management so difficult — with even greater potency than current options.
The Phase 3 TRIUMPH-4 trial results, released via Eli Lilly press release in December 2025, showed retatrutide achieving a mean weight loss of 28.7% at the 12mg dose over 68 weeks — the highest mean weight loss ever recorded in a Phase 3 obesity trial. To put that figure in perspective, the following comparison illustrates where retatrutide sits relative to prior landmark trials:
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GIP/GLP-1 dual agonist | SURMOUNT-1 | 72 weeks | 20.9% |
| Retatrutide 12mg | GLP-1/GIP/glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% |
As of April 2026, an NDA for retatrutide has not yet been filed, and no FDA approval timeline has been publicly confirmed. A peer-reviewed publication of TRIUMPH-4 data is also still pending. This means reta remains an investigational compound — it is not yet available as a prescribed therapy. However, Lilly's sustained revenue growth and the scale of its commercial infrastructure strongly suggest the company has every incentive to move retatrutide through the regulatory process as efficiently as possible.
Strong Q2 earnings also support Lilly's capacity to invest in manufacturing ahead of approval — a critical bottleneck that constrained tirzepatide access in its early commercial phases. The raised full-year 2026 sales forecast signals that Lilly is projecting continued growth, which in turn supports the capital commitments needed to prepare for a retatrutide launch.
Eli Lilly raised its full-year 2026 sales forecast following the Q2 results, a move that reflects both current momentum and forward confidence. For patients on retatrutide waitlists, this matters for a practical reason: a financially strong Lilly is a Lilly that can sustain the clinical, regulatory, and manufacturing investments required to bring reta to market at scale.
The Phase 2 obesity trial data — published in the New England Journal of Medicine in 2023 — had already suggested the extraordinary potential of this compound. At 48 weeks, 100% of participants in the 8mg arm achieved at least 5% weight loss, and 48% of participants in the 12mg arm achieved at least 25% weight loss. Cardiometabolic markers also improved substantially: triglycerides fell by as much as 34% at 24 weeks in the 12mg group, and LDL cholesterol declined by approximately 15–17% in higher-dose arms. Quality of life scores, measured by the SF-36v2, improved across all active dose groups.
TRIUMPH-4 built on those Phase 2 signals and exceeded them. The 12mg titration schedule used in Phase 3 — advancing stepwise from 2mg through 4mg, 6mg, and 9mg before reaching maintenance dosing at week 17 — was designed to manage the dose-dependent gastrointestinal side effects observed in Phase 2, including nausea, diarrhea, and vomiting. Dysesthesia, a sensory side effect, was reported in 20.9% of the 12mg group versus 0.7% of placebo in TRIUMPH-4, which remains an important consideration for shared clinical decision-making once reta reaches approval.
The overall arc is clear: retatrutide is backed by the strongest efficacy signal the obesity pharmacotherapy field has ever seen, supported by a company posting historic quarterly revenues, and advancing through a regulatory pathway that — while not yet complete — is progressing on the back of exceptional Phase 3 results.
For patients who have been following reta closely, who understand the science behind triple agonism, and who are eager to discuss this therapy with a qualified clinician at the appropriate time, the glp3md waitlist exists as an informational resource and a place to stay connected as the regulatory landscape evolves. Joining the waitlist at https://www.glp3md.com does not constitute enrollment in a treatment program, does not guarantee access to any medication, and carries no promise of a prescription — retatrutide is not FDA-approved, and availability cannot be predicted. What the waitlist does offer is timely, evidence-based updates as TRIUMPH-4 peer-reviewed data emerges, as regulatory filings are made, and as the path to approval becomes clearer. Stay informed. The science is moving fast.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.